Highlights Lantheus Holdings, Inc.

Equities

LNTH

US5165441032

Real-time Estimate Cboe BZX Other stock markets 10:12:48 2024-04-29 am EDT			5-day change	1st Jan Change
66.27 ^USD	+1.08%		+4.72%	+6.53%

Apr. 18	B. Riley Raises Price Target on Lantheus Holdings to $99 From $95, Keeps Buy Rating	MT
Mar. 07	Lantheus Holdings Insider Sold Shares Worth $262,005, According to a Recent SEC Filing	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lantheus Holdings Says FDA Approves Expanded Use of Definity in Pediatric Patients	Mar. 04	MT
Lantheus Holdings, Inc. Announces the FDA Approval of Definity (Perflutren Lipid Microsphere) for Pediatric Patients	Mar. 04	CI
Lantheus Holdings Q4 Adjusted Earnings, Revenue Climb; Issues Q1, Full Year Guidance; Shares Rise	Feb. 22	MT
(LNTH) LANTHEUS HOLDINGS Forecasts Q1 EPS Range $1.50 - $1.54	Feb. 22	MT
(LNTH) LANTHEUS HOLDINGS Forecasts Fiscal Year 2024 EPS Range $6.50 - $6.70	Feb. 22	MT
Earnings Flash (LNTH) LANTHEUS HOLDINGS Reports Q4 Revenue $354M	Feb. 22	MT
Earnings Flash (LNTH) LANTHEUS HOLDINGS Reports Q4 EPS $1.75	Feb. 22	MT
Lantheus Holdings, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024	Feb. 22	CI
Lantheus Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Lantheus Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Lantheus Holdings, Inc. Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging	Feb. 13	CI
Lantheus Sued by Novartis Entities for Patent Infringement	Jan. 26	MT
Lantheus Sued by Novartis Entities for Patent Infringement	Jan. 26	MT
Lantheus Sued by Novartis Entities for Patent Infringement	Jan. 26	DJ
Lantheus Holdings, Inc. Announces Acceptance of its First-to-File ANDA for Generic Lutathera (Lutetium Lu 177 Dotatate)	Jan. 11	CI
Lantheus Holdings Expects Higher Full Year 2023 Revenue	Jan. 09	MT
Lantheus Holdings Signs Share Purchase, Licensing Deals With Perspective Therapeutics	Jan. 09	MT
Perspective Therapeutics, Inc. Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability	Jan. 09	CI
Lantheus Holdings, Inc. Provides Revenue Guidance for Its Fiscal Year Ended December 31, 2023	Jan. 09	CI
Lantheus Holdings, Inc. and POINT Biopharma Global Inc. Announce Positive Topline Results from Pivotal Splash Trial in Metastatic Castration-Resistant Prostate Cancer	Dec. 18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Lantheus Holdings, Inc.

Equities

LNTH

US5165441032

Highlights

Filters